Qiagen N.V. Common Shares (NY:QGEN)

45.38 +0.85 (+1.91%)

Official Closing Price Updated: 7:00 PM EDT, Oct 9, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Qiagen N.V. Common Shares

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

QIAGEN Expands AI-Powered Bioinformatics for Research and Drug Discovery

October 06, 2026

From QIAGEN N.V.

Via Business Wire

QIAGEN Completes U.S. QIAstat-Dx Bloodstream Infection Portfolio With FDA Clearance of New Bacteria Detection Panel

September 28, 2026

From QIAGEN N.V.

Via Business Wire

QIAGEN Launches QIAmini to Automate Small-Batch Sample Preparation

September 24, 2026

From QIAGEN N.V.

Via Business Wire

QIAGEN (NYSE:QGEN) Eyes Breakout With Technical Rating 7 and Setup Rating 9 ↗

September 24, 2026

Via Chartmill

QIAGEN Calls Extraordinary General Meeting for Appointment of Jonathan M. Pratt to Managing Board

September 18, 2026

From QIAGEN N.V.

Via Business Wire

QIAGEN Launches QIAsymphony Connect for Automated Clinical Nucleic Acid Extraction

August 27, 2026

From QIAGEN N.V.

Via Business Wire

QIAGEN Appoints Jonathan M. Pratt as Chief Executive Officer

August 24, 2026

From QIAGEN N.V.

Via Business Wire

Qiagen (QGEN) Q2 2026 Earnings Call Transcript ↗

August 13, 2026

Sales beat guidance as Sample Technologies and QIAcuity drive growth momentum.

Via The Motley Fool

Topics Earnings Immigration

QIAGEN Receives U.S. FDA Clearance for First QIAstat-Dx Bloodstream Infection Panel

August 10, 2026

From QIAGEN N.V.

Via Business Wire

Qiagen Q2 Earnings Call Highlights ↗

August 08, 2026

Qiagen (NYSE:QGEN) reported second-quarter 2026 results above its prior outlook, with net sales of $535 million, unchanged year over year on both a reported and constant-exchange-rate basis. The...

Via MarketBeat

Topics Earnings Immigration

QIAGEN Exceeds Q2 2026 Outlook as Pillars Deliver Solid Sales Growth; Reaffirms Full-Year Outlook

August 05, 2026

From QIAGEN N.V.

Via Business Wire

QIAGEN Highlights Molecular Testing Solutions Supporting Response to Growing U.S. Cyclospora Outbreak

July 15, 2026

From QIAGEN N.V.

Via Business Wire

QIAGEN N.V. to Release Results for Q2 2026 and Hold Webcast

July 15, 2026

From QIAGEN N.V.

Via Business Wire

QIAGEN Expands QIAstat-Dx Bloodstream Infection Testing Menu in Europe

July 14, 2026

From QIAGEN N.V.

Via Business Wire

QIAGEN Expands QIAcuity Gene Expression Portfolio to Accelerate Digital PCR Adoption Across Research and Biopharma

June 15, 2026

From QIAGEN N.V.

Via Business Wire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Qiagen N.V. - QGEN

June 02, 2026

From Pomerantz LLP

Via GlobeNewswire

QIAGEN Supports Infectious Disease Research and Surveillance Efforts for Bundibugyo Ebolavirus Outbreak

May 28, 2026

From QIAGEN N.V.

Via Business Wire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Qiagen N.V. - QGEN

May 26, 2026

From Pomerantz LLP

Via GlobeNewswire

QGEN INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving Qiagen N.V.

May 21, 2026

From Kirby McInerney LLP

Via GlobeNewswire

QIAGEN launches QIA Agent, connecting AI-driven scientific guidance across Sample to Insight workflows

May 20, 2026

From QIAGEN N.V.

Via Business Wire

QGEN INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving Qiagen N.V.

May 19, 2026

From Kirby McInerney LLP

Via Business Wire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Qiagen N.V. - QGEN

May 19, 2026

From Pomerantz LLP

Via GlobeNewswire

QIAGEN to advance AI-driven drug discovery with graph-based AI and curated bioinformatics knowledge with NVIDIA

May 19, 2026

From QIAGEN N.V.

Via Business Wire

QIAGEN INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating Qiagen N.V. on Behalf of Qiagen Stockholders and Encourages Investors to Contact the Firm

May 15, 2026

From Bragar Eagel & Squire

Via GlobeNewswire

QGEN SHAREHOLDER ALERT: Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations

May 14, 2026

From Kirby McInerney LLP

Via GlobeNewswire

QIAGEN N.V. INVESTOR ALERT: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud

May 12, 2026

From Kirby McInerney LLP

Via Business Wire

QIAGEN to Appoint Dr. Metin Colpan as Honorary Chairman of the Supervisory Board, Continue Governance Renewal and Propose Increased Returns at 2026 Annual General Meeting

May 12, 2026

From QIAGEN N.V.

Via Business Wire

Water Utility Up Just 8% in a Year Faces $28 Million Position Cut ↗

May 09, 2026

H2O America provides regulated water and wastewater services to over 1.6 million people, focusing on stable, tariff-driven revenue streams.

Via The Motley Fool

Topics Regulatory Compliance

Qiagen (QGEN) Q1 2026 Earnings Transcript ↗

May 07, 2026

Qiagen (QGEN) Q1 2026 Earnings Transcript

Via The Motley Fool

Topics Artificial Intelligence

QIAGEN Plans to Launch New Fully Automated Sample to Insight Workflow and an AI-Enabled Risk Stratification Tool to Advance QuantiFERON Latent TB Testing

May 07, 2026

From QIAGEN N.V.

Via Business Wire

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.